Rosenblatt analyst Barton Crockett raised the firm’s price target on Stagwell (STGW) to $9 from $8 and keeps a Buy rating on the shares. Stagwell returned to peer-high organic growth in Q3, the analyst tells investors in a research note. The firm says the pressure Friday on sector peers, tied to concerns over pharma advertising, should not apply to Stagwell, which sold off its pharma business a year ago.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio